Zhengjun Dai

机构：Technology Holding (United States), Fosun Pharma (China), Zhong Ke San Huan (China), Neusoft (China), Hua Medicine (China) · ORCID：0000-0003-3039-7718

发表论文 35 篇 · 总被引 213 次 · h-index 9

代表论文

• Intratumoral and peritumoral CT radiomics in predicting prognosis in patients with chondrosarcoma: a multicenter study (2024 · Insights into Imaging · 被引 13)
• CT‑based radiomics analysis of consolidation characteristics in differentiating pulmonary disease of non‑tuberculous mycobacterium from pulmonary tuberculosis (2024 · Experimental and Therapeutic Medicine · 被引 11)
• Preoperatively predicting vessels encapsulating tumor clusters in hepatocellular carcinoma: Machine learning model based on contrast-enhanced computed tomography (2024 · World Journal of Gastrointestinal Oncology · 被引 10)
• Ct-based intratumoral and peritumoral radiomics for predicting prognosis in osteosarcoma: A multicenter study (2024 · European Journal of Radiology · 被引 9)
• Noninvasive Prediction of Programmed Cell Death Protein-Ligand 1 Expression in Locally Advanced Non-small Cell Lung Cancer by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Metabolic Habitats: A Multicenter Radiomic and Biological Study (2025 · Annals of Surgical Oncology · 被引 8)
• Deep Learning Radiomics Model of Contrast-Enhanced CT for Differentiating the Primary Source of Liver Metastases (2024 · Academic Radiology · 被引 8)